Equine Arteritis Virus Resistance (EAVR)
Gene or Region: CXCL16 on ECA11: 50.08 Mb – 50.09 Mb (EquCab3.0)
Reference Variant: AGTG or “Resistant”
Mutant Variant: TCAA or TCGA or “Susceptible”
Affected Breeds: Thoroughbred, Saddlebred, Standardbred, Quarter Horse, Warmblood and others
Research Confidence: Preliminary - Strong correlation in early studies, association was present in multiple breeds with strong candidate genes in the region
Explanation of Results: EAVR/EAVR = homozgygous for Equine Arteritis Virus Resistance EAVR/n = heterozygous for Equine Arteritis Virus Resistance n/n = no variant detected
General Description
Equine Viral Arteritis is an infectious disease with a broad range of symptoms, though most horses will not display any overt signs. However, infection with EAV can result in abortions in pregnant mares, and some stallions persistently shed the virus through their semen. Infection prevalence has been reported to vary among breeds, indicating a genetic component to resistance/susceptibility.
The measured SNPs in CXCL16 were reported to be associated with susceptibility of CD3+ lymphocytes to EAV infection. When all four studied breeds were grouped together, the “AGTG” group of alleles was present in 0% of susceptible horses and 100% of resistant horses. Out of these resistant genotypes, 86% were non-shedder, whereas of the susceptible genotype, 74% were shedder. Thus, a horse that genotypes homozygous “AGTG” for all 4 of these SNPs are classified as at a lower risk for susceptibility to infection.
References
Sarkar S et al., “Allelic Variation in CXCL16 Determines CD3+ T Lymphocyte Susceptibility to Equine Arteritis Virus Infection and Establishment of Long- Term Carrier State in the Stallion.” (2016) PLOS Genetics | DOI:10.1371/journal.pgen.1006467.
Go YY et al., “Genome-wide association study among four horse breeds identifies a common haplotype associated with in vitro CD3+ T cell susceptibility/resistance to equine arteritis virus infection.” (2011) J Virol. 85: 13174-84. PMID: 21994447
More Horse Health
Foal Immunodeficiency Syndrome
Foal immunodeficiency syndrome (FIS) is a failure in the development of the adaptive immune system. At 3-6 weeks of age, once the maternal antibodies begin to degrade, foals exhibit signs of anemia, diarrhea, and pneumonia. As these foals fail to respond to treatment for infections, they are humanely euthanized at a young age.
Glanzmann Thrombasthenia
Glanzmann Thrombasthenia (GT) is a blood platelet function disorder, resulting from a reduction in the platelet fibrinogen receptor protein. Clinical signs can be characterized by bleeding on the skin or from the mouth/nostril/gastrointestinal mucosas, and may include skin rashes with blood spots under the skin, nasal bleeding, gastrointestinal and gingival bleedings.
Glycogen Branching Enzyme Deficiency
Glycogen Branching Enzyme Deficiency (GBED) is a lethal recessive disorder characterized by seizures, muscle weakness, respiratory failure, and death. Many affected foals do not make it full term and are aborted or stillborn. Carriers (gbed/n) have no known issues.
Hereditary Equine Regional Dermal Asthenia
Hereditary Equine Regional Dermal Asthenia (HERDA) is a degenerative skin disease that primarily affects the American Quarter Horse. Loose skin is often an early indication of the disease, and severe seromas, hematomas, ulcerations usually develop around 1.5 years of age. There is no cure, and the majority of affected animals have to be euthanized within 2-4 years.